Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15083808 | 0.83 | ESR1 (0.47) | NAMPTESR1HTTALDH1A1HDAC1 | |
| SCHEMBL30147831 | 0.81 | NAMPT (0.52) | NAMPTESR1HTTHDAC1TBXAS1 | |
| SCHEMBL1931436 | 0.80 | TBXAS1 (0.51) | NAMPTESR1ALDH1A1HDAC1TBXAS1 | |
| SCHEMBL20305483 | 0.79 | ESR1 (0.44) | NAMPTESR1HDAC1TBXAS1 | |
| SCHEMBL15232604 | 0.76 | TBXAS1 (0.45) | NAMPTHTTALDH1A1MAPK1TBXAS1 | |
| SCHEMBL22445808 | 0.75 | KDM4E (0.39) | ALDH1A1TBXAS1RAB9AMAPTNPC1 | |
| SCHEMBL28926127 | 0.73 | TSHR (0.46) | HTTALDH1A1RAB9AMAPTNPC1 | |
| SCHEMBL29683753 | 0.73 | HDAC1 (0.48) | NAMPTESR1ALDH1A1HDAC1TBXAS1 | |
| SCHEMBL6301184 | 0.72 | TDP1 (0.52) | HTTALDH1A1RAB9AMAPTNPC1 | |
| SCHEMBL31047551 | 0.71 | NAAA (0.56) | NAMPTESR1HTTALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024254601-A1 | HPGD INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| CN-116730995-B | Hydrazide compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-115803024-A | Composition comprising arylamide derivatives | 中外制药株式会社 | 2023-03-14 | — | — | CN | disclosed |
| CN-115515956-A | Benzimidazole derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| WO-2022068772-A1 | BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-04-07 | — | — | WO | disclosed |
| US-9732078-B2 | Therapeutic use of imidazopyridine derivatives | SANOFI (FR) | 2017-08-15 | — | — | US | disclosed |
| US-9452164-B2 | Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| EP-2942349-A1 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2015-11-11 | — | — | EP | disclosed |
| EP-2800566-B1 | THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES | SANOFI SA (FR) | 2015-10-28 | — | — | EP | disclosed |
| EP-2590976-B1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2015-09-16 | — | — | EP | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| WO-2012004732-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-01-12 | — | — | WO | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| US-20050215584-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PFIZER INC | 2005-09-29 | — | — | US | disclosed |
| US-5547961-A | USING TETRAHYDROIMIDAZOPYRIDINE | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1996-08-20 | — | — | US | disclosed |
| US-5336679-A | Treatment of irritable bowel syndrome | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1994-08-09 | — | — | US | disclosed |
| EP-0532754-A1 | TETRAHYDROIMIDAZOPYRIDINE DERIVATIVE OR ITS SALT | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1993-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215584-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | CHRNA7, UGT2B7, CHRNA5 | NAMPT 873/4885ESR1 1287/4885HTT 1792/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | NAMPT 2640/4885ESR1 978/4885HTT 4056/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | NAMPT 1776/4885ESR1 1955/4885HTT 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.